Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Specific mutations in Wnt/β-catenin and mitogen activated protein kinase pathways have been reported to have associations with tumorigenesis of hepatocellular carcinoma (HCC). The clinical implications of CTNNB1 (the coding gene for β-catenin) and BRAF mutations in advanced HCC and their associations with prognosis have not been well studied. Patients and Methods: We reviewed patients with HCC who were screened for enrollment in clinical trials of first-line molecular-targeted therapy for advanced diseases between Mar 2006 and Aug 2009 in a tertiary medical center. Only patients with adequate pathologic specimens obtained at the time of developing advanced disease were included. Direct sequencing of exon 3 of CTNNB1 and exon 15 of BRAF were performed to detect mutations. Associations between the specific mutations and clinicopathologic features or survival of the patients were analyzed. Results: Eighty-one patients were enrolled in the study, with the median age of 56.3 years. Among them, 55 (67.9%) patients were seropositive for hepatitis B virus (HBV) surface antigen; 19 (23.5%) patients were seropositive for antibody against hepatitis C virus (HCV); 77 (95.1%) patients had BCLC stage C; 42 (51.9%) patients had a CLIP score ≤ 3. Missense mutations of CTNNB1 were identified in 10 (12.3%) patients. BRAF mutations were found in 4 (4.9%) patients, including 3 missense and 1 silent mutations. The two gene mutations were mutually exclusive. The median overall survival of patients with and without CTNNB1 mutation were 7.5 and 6.5 months, respectively (P = 0.430). The median overall survival of patients with and without BRAF mutation were 2.8 and 6.6 months, respectively (p = 0.350). CTNNB1 or BRAF mutation had no statistically significant associations with the gender, the ECOG performance status, HBV infection, HCV infection, alpha-fetoprotein levels, prior local treatment, macrovascular invasion, extrahepatic metastasis, BCLC stages, Okuda stages or CLIP scores. Patients with CTNNB1 mutations were more likely to be > 70 years old than patients without CTNNB1 mutations (40% vs. 11.3%, p = 0.017). Conclusions: CTNNB1 and BRAF mutations were relatively rare events in patients with advanced HCC. CTNNB1 mutations were associated with older ages in this specific population (This study was supported by the grant NTUHYLN005). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4584. doi:1538-7445.AM2012-4584

[Expression and Exon 3 Mutation of Beta-Catenin in Human Hepatocellular Carcinoma].

Mutation and Overexpression of the Β-Catenin Gene May Play an Important Role in Primary Hepatocellular Carcinoma among Chinese People

Β-Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma

Abnormal Beta-Catenin Gene Expression with Invasiveness of Primary Hepatocellular Carcinoma in China

Wnt Signaling in Hepatocellular Carcinoma: Analysis of Mutation and Expression of Beta-Catenin, T-cell Factor-4 and Glycogen Synthase Kinase 3-Beta Genes.

Increased Sensitivity To Wnt/Beta-Catenin Inhibitors In Hepatocellular Carcinoma Cells Harboring Activating Mutation Of Beta-Catenin

Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

Expression and clinical significance of GS,E-cadherin and β-catenin in hepatocellular carcinoma

Beta-Catenin (Ctnnb1) And Braf Mutations In Advanced Hepatocellular Carcinoma

Alterations of Beta-Catenin and Tcf-4 Instead of Gsk-3 Beta Contribute to Activation of Wnt Pathway in Hepatocellular Carcinoma

β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma.

β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation

Significance of Cathepsin D and Chromogranin A Expression in Human Primary Hepatocellular Carcinomas

Expression of CCT Subunit Γ in Aflatoxin B1-induced Hepatocarcinogenesis in Wistar Rats

Expression of SRF, E-cadherin and β-catenin in hepatocellular carcinoma and its clinical significances

Association of Htcf—4 Gene Expression and Mutation with Clinicopathological Characteristics of Hepatocellular Carcinoma

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Expression and Prognostic Impact of NTF3 and TrkC in Hepatocellular Carcinoma.

Cytoplasmic And/or Nuclear Expression of Β-Catenin Correlate with Poor Prognosis and Unfavorable Clinicopathological Factors in Hepatocellular Carcinoma: a Meta-Analysis.

GCNT3 regulated MUC13 to promote the development of hepatocellular carcinoma through the GSK3β/β-catenin pathway

Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression